<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04917874</url>
  </required_header>
  <id_info>
    <org_study_id>B-VEC-EX-02</org_study_id>
    <nct_id>NCT04917874</nct_id>
  </id_info>
  <brief_title>A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa</brief_title>
  <official_title>Open Label Treatment of Beremagene Geperpavec (B-VEC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Krystal Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Krystal Biotech, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 78-week (approximately a year and a half) open-label extension study of Beremagene&#xD;
      Geperpavec (B-VEC), for participants aged 6 months and older, who have been diagnosed with&#xD;
      Dystrophic Epidermolysis Bullosa (DEB). Participants will be dosed weekly with the topical&#xD;
      B-VEC therapy. The primary endpoint will be to assess long term safety and tolerability of&#xD;
      the topical gene therapy. The study is for those who participated in Phase III study, as well&#xD;
      as, new participants who were unable to participate in the Phase III study, who meet all&#xD;
      enrollment criteria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse event (AE) or serious adverse events (SAE)</measure>
    <time_frame>Up to 78 weeks</time_frame>
    <description>An Adverse Event (AE) is any untoward medical occurrence in a clinical investigation participant administered an investigational product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, disease or exacerbation of a pre-existing condition temporally associated with the use of an investigational product.</description>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Dystrophic Epidermolysis Bullosa</condition>
  <condition>DEB - Dystrophic Epidermolysis Bullosa</condition>
  <condition>Recessive Dystrophic Epidermolysis Bullosa</condition>
  <condition>Dominant Dystrophic Epidermolysis Bullosa</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Open Label Topical Beremagene Geperpavec (B-VEC)</intervention_name>
    <description>Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to give consent/assent&#xD;
&#xD;
          -  Clinical diagnosis of epidermolysis bullosa&#xD;
&#xD;
          -  Confirmation of diagnosis (either DDEB or RDEB) by genetic testing including COL7A1.&#xD;
&#xD;
          -  Age: 6 months of age and older at the time of informed consent/assent&#xD;
&#xD;
          -  Women of childbearing age must be willing to use reliable birth control method&#xD;
             throughout the treatment duration and for 3 months following the last treatment&#xD;
             application&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diseases or conditions that could interfere with the assessment of safety of the study&#xD;
             treatment and compliance of the participant with study visits/procedures, as&#xD;
             determined by the Investigator&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Active infection in the area that will undergo administration, that the Investigator&#xD;
             believes will negatively impact the IP application&#xD;
&#xD;
          -  Known allergy to any of the constituents of the product&#xD;
&#xD;
          -  Concurrent skin transplant or mesh skin grafting; if the participant is currently&#xD;
             having transplantation or grafting surgeries they must wait until the transplant has&#xD;
             begun to heal and the graft has absorbed prior to initiating B-VEC therapy&#xD;
&#xD;
          -  Participation in an interventional gene therapy clinical trial within the past three&#xD;
             (3) months (not including B-VEC administration)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Brittani Agostini</last_name>
    <phone>4125865830</phone>
    <email>bagostini@krystalbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mission Dermatology Center</name>
      <address>
        <city>Rancho Santa Margarita</city>
        <state>California</state>
        <zip>92688</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guida Pinto</last_name>
      <phone>949-858-3376</phone>
      <phone_ext>108</phone_ext>
      <email>gpinto.missionderm@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Shireen Guide, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sinem Bagci</last_name>
      <phone>650-484-6878</phone>
      <email>isbagci@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Marinkovich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatric Skin Research</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edilmary Urdaneta</last_name>
    </contact>
    <investigator>
      <last_name>Mercedes Gonzalez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Amy Paller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anne Lucky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension Seton- Dell's Children Medical Group</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Moise Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DEB</keyword>
  <keyword>Krystal Biotech</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
    <mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

